AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Research output: Contribution to journalArticle

Abstract

The pace of anticancer drug discovery and development has accelerated over recent years based upon a better understanding of tumour biology at the molecular level. Modern drug development has moved from empiricism to rational design and this was the theme of the inaugural meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Washington DC, November 16 - 19.1999. This was an excellent meeting where state of the art research in the areas of drug discovery, development and clinical evaluation of new cancer therapeutics was presented. A few of the highlights of this meeting are presented in this article but further details can he found in a supplement to Clinical Cancer Research (1999) 5:3729-3897, where all abstracts accepted for the meeting are published. This meeting is set to become the premier meeting for scientists and clinicians involved in all aspects of anticancer drug development (i.e., from bench to the bedside) and the next meeting will take place in Amsterdam on November 7-10, 2000.
Original languageEnglish
Pages (from-to)631-8
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2000
Externally publishedYes

Fingerprint

Drug Discovery
Neoplasms
Empiricism
Therapeutics
Research
Pharmaceutical Preparations
Molecular Biology

Cite this

@article{cf64a7d694d2414bbb1b8472fff8db44,
title = "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
abstract = "The pace of anticancer drug discovery and development has accelerated over recent years based upon a better understanding of tumour biology at the molecular level. Modern drug development has moved from empiricism to rational design and this was the theme of the inaugural meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Washington DC, November 16 - 19.1999. This was an excellent meeting where state of the art research in the areas of drug discovery, development and clinical evaluation of new cancer therapeutics was presented. A few of the highlights of this meeting are presented in this article but further details can he found in a supplement to Clinical Cancer Research (1999) 5:3729-3897, where all abstracts accepted for the meeting are published. This meeting is set to become the premier meeting for scientists and clinicians involved in all aspects of anticancer drug development (i.e., from bench to the bedside) and the next meeting will take place in Amsterdam on November 7-10, 2000.",
keywords = "Drug Design, Humans, National Institutes of Health (U.S.), Neoplasms/drug therapy, Research Support as Topic, United States",
author = "Phillips, {R M}",
year = "2000",
month = "3",
doi = "10.1517/13543784.9.3.631",
language = "English",
volume = "9",
pages = "631--8",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "3",

}

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. / Phillips, R M.

In: Expert Opinion on Investigational Drugs, Vol. 9, No. 3, 03.2000, p. 631-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

AU - Phillips, R M

PY - 2000/3

Y1 - 2000/3

N2 - The pace of anticancer drug discovery and development has accelerated over recent years based upon a better understanding of tumour biology at the molecular level. Modern drug development has moved from empiricism to rational design and this was the theme of the inaugural meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Washington DC, November 16 - 19.1999. This was an excellent meeting where state of the art research in the areas of drug discovery, development and clinical evaluation of new cancer therapeutics was presented. A few of the highlights of this meeting are presented in this article but further details can he found in a supplement to Clinical Cancer Research (1999) 5:3729-3897, where all abstracts accepted for the meeting are published. This meeting is set to become the premier meeting for scientists and clinicians involved in all aspects of anticancer drug development (i.e., from bench to the bedside) and the next meeting will take place in Amsterdam on November 7-10, 2000.

AB - The pace of anticancer drug discovery and development has accelerated over recent years based upon a better understanding of tumour biology at the molecular level. Modern drug development has moved from empiricism to rational design and this was the theme of the inaugural meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Washington DC, November 16 - 19.1999. This was an excellent meeting where state of the art research in the areas of drug discovery, development and clinical evaluation of new cancer therapeutics was presented. A few of the highlights of this meeting are presented in this article but further details can he found in a supplement to Clinical Cancer Research (1999) 5:3729-3897, where all abstracts accepted for the meeting are published. This meeting is set to become the premier meeting for scientists and clinicians involved in all aspects of anticancer drug development (i.e., from bench to the bedside) and the next meeting will take place in Amsterdam on November 7-10, 2000.

KW - Drug Design

KW - Humans

KW - National Institutes of Health (U.S.)

KW - Neoplasms/drug therapy

KW - Research Support as Topic

KW - United States

U2 - 10.1517/13543784.9.3.631

DO - 10.1517/13543784.9.3.631

M3 - Article

VL - 9

SP - 631

EP - 638

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 3

ER -